- Home
- CASS vs PRAX Comparison
CASS vs PRAX Comparison
Compare CASS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASS
- PRAX
- Stock Information
- Founded
- CASS 1906
- PRAX 2015
- Country
- CASS United States
- PRAX United States
- Employees
- CASS N/A
- PRAX N/A
- Industry
- CASS Business Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- CASS Consumer Discretionary
- PRAX Health Care
- Exchange
- CASS Nasdaq
- PRAX Nasdaq
- Market Cap
- CASS 586.3M
- PRAX 599.7M
- IPO Year
- CASS 1996
- PRAX 2020
- Fundamental
- Price
- CASS $39.48
- PRAX $33.79
- Analyst Decision
- CASS Buy
- PRAX Strong Buy
- Analyst Count
- CASS 1
- PRAX 9
- Target Price
- CASS $45.00
- PRAX $123.33
- AVG Volume (30 Days)
- CASS 42.9K
- PRAX 570.3K
- Earning Date
- CASS 04-17-2025
- PRAX 05-12-2025
- Dividend Yield
- CASS 3.14%
- PRAX N/A
- EPS Growth
- CASS N/A
- PRAX N/A
- EPS
- CASS 1.53
- PRAX N/A
- Revenue
- CASS $220,944,000.00
- PRAX $8,553,000.00
- Revenue This Year
- CASS N/A
- PRAX N/A
- Revenue Next Year
- CASS $7.70
- PRAX $789.73
- P/E Ratio
- CASS $26.19
- PRAX N/A
- Revenue Growth
- CASS 2.32
- PRAX 249.53
- 52 Week Low
- CASS $37.99
- PRAX $26.70
- 52 Week High
- CASS $47.14
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- CASS 38.01
- PRAX 43.73
- Support Level
- CASS $38.23
- PRAX $28.79
- Resistance Level
- CASS $40.00
- PRAX $30.88
- Average True Range (ATR)
- CASS 1.67
- PRAX 3.07
- MACD
- CASS -0.18
- PRAX 0.88
- Stochastic Oscillator
- CASS 23.19
- PRAX 56.05
About CASS Cass Information Systems Inc
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.